<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">Among many other ISGs, human MxA has been shown to be particularly potent in inhibiting IAV replication 
 <italic>in vitro</italic> as well as 
 <italic>in vivo</italic>
 <sup>
  <xref ref-type="bibr" rid="CR9">9</xref>–
  <xref ref-type="bibr" rid="CR11">11</xref>
 </sup>. Its importance is further emphasized by the fact that all human-adapted IAVs, including all pandemic viruses, have evolved partial resistance towards MxA antiviral activity through mutations in their NP
 <sup>
  <xref ref-type="bibr" rid="CR9">9</xref>
 </sup>. MxA belongs to the family of large dynamin-like GTPases and localizes to the cytoplasm, in contrast to IAV replication which occurs in the nucleus. To date, the mechanism by which MxA inhibits IAV replication is still unclear and somewhat controversial
 <sup>
  <xref ref-type="bibr" rid="CR12">12</xref>,
  <xref ref-type="bibr" rid="CR13">13</xref>
 </sup>. However, there is general agreement that a very early step of the IAV replication cycle is affected
 <sup>
  <xref ref-type="bibr" rid="CR14">14</xref>–
  <xref ref-type="bibr" rid="CR16">16</xref>
 </sup>.
</p>
